Therapy with irritren in rheumatic degenerative diseases.
The antirheumatic effect of a new nonsteroidal antiinflammatory drug, irritren, a derivative of arylacetic acid namely ionazolac calcium was studied. The favourable effect of irritren treatment in reactivated arthrosis was compared to that of indomethacin. To this end 40 patients were divided into two groups of 20 patients each who were treated for 14 days with: irritren in daily doses of 3 X 200 mg-Group I, and with indomethacin in daily doses of 3 X 25 mg-group II. The results obtained at the end of the experiment showed a marked decrease of joint pain and of inflammation in 85% of the patients in group I while in group II good results were obtained in only 75% of the patients. The excellent digestive tolerance and the absence of untoward side effects situated irritren as clearly superior to indomethacin. The drug appeared as most useful especially in reactivated arthritic diseases.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D011720:Pyrazoles; C017472:lonazolac; D007213:Indomethacin